Skip to main content
Premium Trial:

Request an Annual Quote

Cofactor Genomics Collaborates with Kentucky Network on Sequencing Data

NEW YORK (GenomeWeb News) – Cofactor Genomics today said it has completed a collaboration with a network of researchers in Kentucky to design experiments and generate and analyze next-generation sequencing data for the state.

As part of the collaboration, the St. Louis-based company "leveraged its [design and analysis] process to improve the efficiencies and effectiveness of the sequencing experiments and provide more useful results," to the Kentucky Biomedical Research Infrastructure Network, it said.

KBRIN is a network of biomedical researchers in Kentucky funded through a National Center for Research Resources Idea Networks for Biomedical Research Excellence (INBRE) grant. It aims to expand biomedical research in the state by supporting "Kentucky's next generation of biomedical researchers."

KBRIN's collaboration with Cofactor has resulted in bringing next-gen sequencing design and analysis to Kentucky's research community, KBRIN Project Director Nigel Cooper said, adding that the KBRIN-INBRE program's goal is to build collaborative research and develop a statewide bioinformatics structure.

Institutions benefitting from the collaboration with Cofactor include Morehead State University, Northern Kentucky University, Western Kentucky University, Eastern Kentucky University, the University of Louisville, and the University of Kentucky.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more